Researchers develop new dichloroacetate formulation for cancer treatment

April 16, 2014 by Jessica Luton
Researchers develop new dichloroacetate formulation for cancer treatment
Shanta Dhar, right, and Sean Marrache

Health forums were abuzz in 2007 with news that a simple, inexpensive chemical may serve as a viable treatment to many forms of cancer. The drug dichloroacetate, or DCA, was touted as a cure-all, but after years of work, scientists are still searching for ways to make the unique treatment as effective as possible.

Now, researchers at the University of Georgia have discovered a new way to deliver this drug that may one day make it a viable treatment for numerous forms of cancer. They published their findings in the American Chemical Society's journal ACS Chemical Biology.

"DCA shows great promise as a potential , but the drug doesn't find and attack very efficiently in the doses researchers are testing," said Shanta Dhar, an assistant professor of chemistry in the UGA Franklin College of Arts and Sciences. "We have developed a new compound based on DCA that is three orders of magnitude more potent than standard treatments."

Every cell in the body needs energy to divide and grow, and most of them do this by breaking down sugar. When cells misbehave, they are normally deprived of their food and die in a process called apoptosis.

Cancerous cells, however, find a way around the natural order by discovering other sources of energy. Dhar's technology, which she calls Mito-DCA, destroys the cancer by focusing on a part of the cell called mitochondria, commonly known as the powerhouse of cells because they generate most of the cell's chemical energy.

"By targeting the mitochondria, we can force cancerous cells to die just as regular malfunctioning cells would," said Dhar, who is part of the UGA Cancer Center. "But the drug we have developed affects only cancerous cells, leaving undisturbed."

In their experiments, Dhar and her research team exposed cancer cells to Mito-DCA. The results showed that the engineered chemical substance was able to switch the glycolysis-based metabolism of cancer cells to glucose oxidation, meaning that the cancer cells can once again die via apoptosis.

Mito-DCA also suppressed the production of lactic acid in , which allows them to avoid detection by the body's immune system. With this cloaking device damaged, the body's own T-cells are better able to recognize tumors and eliminate them.

While the UGA researchers' model focused specifically on prostate cancer, Dhar is hopeful that their technique may prove useful for other forms of cancer.

"This is only the beginning of this project," she said. "We will continue to test Mito-DCA and find new avenues for treatment."

Explore further: New aspirin-based prodrug may prevent damage caused by chemotherapy

More information: The full paper is available online: pubs.acs.org/doi/ipdf/10.1021/cb400944y

Related Stories

New aspirin-based prodrug may prevent damage caused by chemotherapy

January 10, 2014
(Medical Xpress)—Researchers at the University of Georgia have developed a new prodrug that promises to reduce many of the negative side effects caused by cisplatin, a commonly prescribed chemotherapy treatment.

How tumors become resistant to drugs, and how process can be reversed to inhibit cancer growth

April 10, 2014
Researchers at the Hebrew University of Jerusalem's Faculty of Medicine have discovered a process whereby tumor cells become resistant to specific drugs, a finding that could significantly influence how anti-cancer drugs ...

New drug raises potential for cancer treatment revolution

March 21, 2014
(Medical Xpress)—A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates. A new study at the University of Warwick, published today ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.